Clinical significance of serum cytokeratin 19 fragment in the prediction of chemotherapy efficacy and prognosis in patients with advanced non-small cell lung cancer

Chinese Journal of Lung Cancer

Volumn 13, Issue 10, 2010, Pages 954-961

  Xu, Chong'an ^a   Liu, Jiali ^a   Xing, Lili ^a   Liu, Shu ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

Chemotherapy efficacy; CYFRA21 1; Lung neoplasms; Predictor factors; Prognostic factors; Radiological response

Indexed keywords

CARBOPLATIN; CISPLATIN; CYTOKERATIN 19 FRAGMENT; DOCETAXEL; ETOPOSIDE; GEMCITABINE; NAVELBINE; PACLITAXEL; PLATINUM;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER PATIENT; CANCER SURVIVAL; DRUG EFFICACY; ELECTROCHEMICAL ANALYSIS; FEMALE; HUMAN; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; PROTEIN EXPRESSION; RECEIVER OPERATING CHARACTERISTIC; SEROLOGY; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KERATIN-19; LUNG NEOPLASMS; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; PROGNOSIS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 78049387187     PISSN: 10093419     EISSN: 19996187     Source Type: Journal    
DOI: 10.3779/j.issn.1009-3419.2010.10.05     Document Type: Article

References (23)

1. Kubota K, Kawahara M, Ogawara M, et al. Vinorelbine plus gemcitabine followed by docetaxel versus carboplatin plus paclitaxel in patients with advanced non-small-cell lung cancer: a randomised, open-label, phase III study. Lancet Oncol, 2008, 9(12): 1135-1142.
2. Novello S, Falcone A, Crinò L, et al. Randomised multicenter phase II study of two schedules of docetaxel and gemcitabine or cisplatin/gemcitabine followed by docetaxel as first line treatment for advanced non-small cell lung cancer. Lung Cancer, 2009, 66(3): 327-332.
3. Radhakrishnan A, Bitran JD, Milton DT, et al. Docetaxel and oxaliplatin as first-line therapy for advanced non-small cell lung cancer: a phase II trial. J Chemother, 2009, 21(4): 439-444.
4. Ollivier L, Leclère J, Thiesse P, et al. Measurement of tumour response to cancer treatment: morphologic imaging role. Bull Cancer, 2007, 94(2): 171-177.
5. Suzuki C, Jacobsson H, Hatschek T, et al. Radiologic measurements of tumor response to treatment: practical approaches and limitations. Radiographics, 2008, 28(2): 329-344.
6. Nisman B, Biran H, Heching N, et al. Prognostic role of serum cytokeratin 19 fragments in advanced non-small-cell lung cancer: association of marker changes after two chemotherapy cycles with different measures of clinical response and survival. Br J Cancer 2008, 98(1): 77-79.
7. Załeska M, Szturmowicz M, Zych J, et al. The significance of the serum tumour markers as a prognostic and predictor factors in non-small cell lung cancer patients. Pneumonol Alergol Pol, 2005, 73(3): 270-276.
8. Weber WA. Assessing tumor response to therapy. J Nucl Med, 2009, 50(Suppl 1): 1S-10S.
9. Kim MS, Lee SY, Cho WH, et al. Effect of increases in tumor volume after neoadjuvant chemotherapy on the outcome of stage II osteosarcoma regardless of histological response. J Orthop Sci, 2009, 14(3): 292-297.
10. Wahl RL, Jacene H, Kasamon Y, et al. From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors. J Nucl Med, 2009, 50(Suppl 1): 122S-150S.
11. Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin liver Dis, 201, 30(1): 52-60.
12. Sasaki R, Komaki R, Macapinlac H, et al. [18F] Fluorodeoxyglucose uptake by positron emission tomography predicts outcome of non-small-cell lung cancer. J Clin Oncol, 2005, 23: 1136-1143.
13. Hoekstra CJ, Stroobants SG, Smit EF, et al. Prognostic relevance of response evaluation using [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography in patients with locally advanced non-small-cell lung cancer. J Clin Oncol, 2005, 23(33): 8362-8370.
14. Berger M, Gould MK, Barnett PG. The coat of positron emission tomography in six United States Veterans Affairs hospitals and two academic medical centers. Am J Roentgenol, 2003, 181(2): 359-365. (Pubitemid 36913572)
15. Kotowicz B, Fuksiewicz M, Kowalska M, et al. The value of tumor marker and cytokine analysis for the assessment of regional lymph node status in cervical cancer patients. Int J Gynecol Cancer, 2008, 18(6): 1279-1284.
16. Choueiri TK, Xie W, D'Amico AV et al. Time to prostate-specific antigen nadir independently predicts overall survival in patients who have metastatic hormone-sensitive prostate cancer treated with androgen-deprivation therapy. Cancer, 2009, 115(5): 981-987.
17. Meyer T, Rustin GJS. Role of tumor markers in monitoring epithelial ovarian cancer. Br J Cancer, 2000, 82: 1535-1538. (Pubitemid 30204358)
18. Riedinger JM, Bonnetain F, Basuyau JP, et al. Change in CA 125 levels after the first cycle of induction chemotherapy is an independent predictor of epithelial ovarian tumour outcome. Ann Oncol, 2007, 18(5): 881-885. (Pubitemid 47054085)
19. Wong D, Ko AH, Hwang J, et al. Serum CA19-9 decline compared to radiographic response as a surrogate for clinical outcomes in patients with metastatic pancreatic cancer receiving chemotherapy. Pancreas, 2008, 37(3): 269-274.
20. Holdenrieder S, Stieber P, von Pawel J, et al. Circulating nucleosomes predict the response to chemotherapy in patients with advanced non-small cell lung cancer. Clin Cancer Res, 2004, 10: 5981-5987. (Pubitemid 39287502)
21. Holdenrieder S, von Pawel J, Dankelmann E, et al. Nucleosomes and CYFRA21-1 indicate tumor response after one cycle of chemotherapy in recurrent non-small cell lung cancer. Lung Cancer 2009, 63(1): 128-135.
22. Merle P, Janicot H, Filaire M, et al. Early CYFRA21-1 variation predicts tumor response to chemotherapy and survival in locally advanced non-small cell lung cancer patients. Int J Biol Markers, 2004, 19: 310-315. (Pubitemid 40124853)
23. Ardizzoni A, Cafferata MA, Tiseo M, et al. Decline in serum carcinoembryonic antigen and cytokeratin 19 fragment during chemotherapy predicts objective response and survival in patients with advanced nonsmall cell lung cancer. Cancer, 2006, 107(12): 2842-2849.